The NeuroOne OneRF Ablation System is a new device with FDA-cleared technology designed for both diagnosing and treating ...

NeuroOne (Nasdaq:NMTC) announced today that it filed an FDA 510(k) submission for its trigeminal nerve ablation technology.

Ablation of the posterior nasal nerve leads to durable reductions in symptoms of chronic rhinitis, new research shows.

Technologies has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance.

A warning to stop using certain Novasight Hybrid diagnostic intravascular catheters was distributed by the FDA. Moderate- and ...

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

Innoblative Designs announced today that it received FDA investigational device exemption (IDE) for its Sira RFA ...

IceCure Medical Ltd. announced findings from three investigator-initiated studies of the company’s ProSense system for the ...

There were no gastric and adrenal puncture instances among patients who underwent radio-ablation in both groups. 2. Majority ...

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from ...